Format

Send to

Choose Destination
J Autoimmun. 2019 Feb;97:70-76. doi: 10.1016/j.jaut.2018.10.010. Epub 2018 Nov 19.

Targeting interferon activity to dendritic cells enables in vivo tolerization and protection against EAE in mice.

Author information

1
Cytokine Receptor Laboratory, VIB Medical Biotechnology Center, Ghent University, 9000, Ghent, Belgium.
2
Institute of Neuropathology, Faculty of Medicine, University of Freiburg, 79106, Freiburg, Germany.
3
CNRS UMR 5235, University Montpellier, 34095, Montpellier, France.
4
Institute of Neuropathology, Faculty of Medicine, University of Freiburg, 79106, Freiburg, Germany; BIOSS Centre for Biological Signalling Studies, University of Freiburg, 79106, Freiburg, Germany.
5
Orionis Biosciences, 9052, Gent, Belgium.
6
Cytokine Receptor Laboratory, VIB Medical Biotechnology Center, Ghent University, 9000, Ghent, Belgium; Orionis Biosciences, 9052, Gent, Belgium. Electronic address: jan.tavernier@vib-ugent.be.

Abstract

Type I Interferon (IFN) is widely used for multiple sclerosis (MS) treatment, but its side effects are limiting and its mechanism of action still unknown. Furthermore, 30-50% of MS patients are unresponsive, and IFN can even induce relapses. Fundamental understanding of the cellular target(s) of IFN will help to optimize treatments by reducing side effects and separating beneficial from detrimental effects. To improve clinical systemic IFN usage, we are developing AcTaferons (Activity-on-Target IFNs = AFNs), optimized IFN-based immunocytokines that allow cell-specific targeting. In experimental autoimmune encephalitis (EAE) in mice, high dose WT mIFNα could delay disease, but caused mortality and severe hematological deficits. In contrast, AFN targeted to dendritic cells (DC, via Clec9A) protected without mortality or hematological consequences. Conversely, CD8-targeted AFN did not protect and exacerbated weight loss, indicating the presence of both protective and unfavorable IFN effects in EAE. Comparing Clec9A-, XCR1-and SiglecH-targeting, we found that targeting AFN to plasmacytoid (p) and conventional (c) DC is superior and non-toxic compared to WT mIFN. DC-targeted AFN increased pDC numbers and their tolerogenic potential, evidenced by increased TGFβ and IDO synthesis and regulatory T cell induction. In addition, both regulatory T and B cells produced significantly more immunosuppressive TGFβ and IL-10. In conclusion, specific DC-targeting of IFN activity induces a robust in vivo tolerization, efficiently protecting against EAE, without noticeable side effects. Thus, dissecting positive and negative IFN effects via cell-specific targeting may result in better and safer MS therapy and response rates.

KEYWORDS:

AcTaferon; Dendritic cells; EAE; Interferon; Tolerization

PMID:
30467068
DOI:
10.1016/j.jaut.2018.10.010

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center